Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

  title={Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.},
  author={Anas Younes and Yasuhiro Oki and Robert Gregory Bociek and John Kuruvilla and Michelle A Fanale and Sattva S. Neelapu and Amanda R Copeland and Daniela Buglio and Ahmed Galal and Jeffrey M. Besterman and Zuomei Li and Michel Drouin and Tracy Patterson and Michael R. Ward and Jessica K Paulus and Yuan Ji and L Jeffrey Medeiros and Robert Martell},
  journal={The Lancet. Oncology},
  volume={12 13},
BACKGROUND The prognosis of patients with relapsed Hodgkin's lymphoma, especially those who relapse after stem-cell transplantation, is poor, and the development of new agents for this patient population is an unmet medical need. We tested the safety and efficacy of mocetinostat, an oral isotype-selective histone deacetylase inhibitor, in patients with relapsed classical Hodgkin's lymphoma. METHODS Patients with relapsed or refractory classical Hodgkin's lymphoma aged 18 years or older were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 12 times over the past 90 days. VIEW TWEETS
53 Citations
33 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 53 extracted citations


Publications referenced by this paper.
Showing 1-10 of 33 references

Final analysis: phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant

  • A Sureda, A Younes, D Ben-Yehuda
  • Blood
  • 2010

Similar Papers

Loading similar papers…